Review-Testosterone and risk of breast cancer: Appraisal of existing evidence

Hormone Molecular Biology and Clinical Investigation

Volumn 2, Issue 1, 2010, Pages 177-190

  Traish, Abdulmaged M ^a   Fetten, Katharina ^a   Miner, Martin ^b,c   Hansen, Michael L ^d,e   Guay, Andre ^f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIRIAM HOSPITAL   (United States)

^c Swansea Family Practice   (United States)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e Copenhagen Cardiovascular Clinic ^*  (Denmark)

^f LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

androgen excess; androgen therapy; aromatase inhibitors; breast cancer; estradiol; hormone replacement therapy; menopause; polycystic ovary disease; sex hormone binding globulin; testosterone

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; TESTOSTERONE;

ANDROGEN THERAPY; ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; BREAST CANCER CELL LINE; BREAST DENSITY; CANCER INCIDENCE; CANCER INHIBITION; CANCER RECURRENCE; CANCER RISK; ENDOCRINE DISEASE; FEMALE TO MALE TRANSGENDER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; TESTOSTERONE BLOOD LEVEL;

EID: 85011322217     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.024     Document Type: Article

References (101)

1. Traish AM., Feeley RJ., Guay AT. Testosterone therapy in women with gynecological and sexual disorders: a triumph of clinical endocrinology from 1938 to 2008. J Sex Med 2009;6: 334-51.
2. Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007;88:1-17.
3. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. J Sex Med 2007;4:859-66.
4. Braunstein GD. The Endocrine Society Clinical Practice Guideline and The North American Menopause Society position statement on androgen therapy in women: another one of Yogi's forks. J Clin Endocrinol Metab 2007;92:4091-3.
5. Shufelt CL., Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63:63-6.
6. Schover LR. Androgen therapy for loss of desire in women: Is the benefit worth the breast cancer risk? Fertil Steril 2008; 90:129-40.
7. Rosner W., Auchus RJ., Azziz R., Sluss PM., Raff H. Position statement: utility., limitations., and pitfalls in measuring testosterone: an endocrine society position statement. J Clin Endo-crinol Metab 2007;92:405-13.
8. Somboonporn W., Davis SR. National Health and Medical Research Council. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004;25:374-88.
9. Birrell SN., Bentel JM., Hickey TE., Ricciardelli C., Weger MA., Horsfall DJ., Tilley WD. Androgens induce divergent prolif-erative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52:459-67.
10. Beattie MS., Costantino JP., Cummings SR., Wickerham DL., Vogel VG., Dowsett M., Folkerd EJ., Willett WC., Wolmark N., Hankinson SE. Endogenous sex hormones., breast cancer risk., and tamoxifen response: an ancillary study in the NSABP breast cancer prevention trial (P-1). J Natl Cancer Inst 2006; 98:110-5.
11. Anders CK., Carey LA. Biology., metastatic patterns., and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009;9:S73-S81.
12. Smith IE., Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42.
13. Mouridsen H., Giobbie-Hurder A., Goldhirsch A., Thürlimann B., Paridaens R., Smith I., Mauriac L., Forbes JF., Price KN., Regan MM., Gelber RD., Coates AS. BIG 1-98 Collaborative Group., letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76.
14. Goss PE., Ingle JN., Martino S., Robert NJ., Muss HB., Piccart MJ., Castiglione M., Tu D., Shepherd LE., Pritchard KI., Livingston RB., Davidson NE., Norton L., Perez EA., Abrams JS., The-rasse P., Palmer MJ., Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349: 1793-802.
15. Coombes RC., Hall E., Gibson LJ., Paridaens R., Jassem J., Delo-zier T., Jones SE., Alvarez I., Bertelli G., Ortmann O., Coates AS., Bajetta E., Dodwell D., Coleman RE., Fallowfield LJ., Mic-kiewicz E., Andersen J., Lønning PE., Cocconi G., Stewart A., Stuart N., Snowdon CF., Carpentieri M., Massimini G., Bliss JM., van de Velde C., Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen ther-apy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
16. Thurlimann B., Keshaviah A., Coates AS., Mouridsen H., Mau-riac L., Forbes JF., Paridaens R., Castiglione-Gertsch M., Gelber RD., Rabaglio M., Smith I., Wardley A., Price KN., Goldhirsch A., Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postme-nopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
17. Rossi E., Morabito A., Di Rella F., Esposito G., Gravina A., Labo-nia V., Landi G., Nuzzo F., Pacilio C., De Maio E., Di Maio M., Piccirillo MC., De Feo G., D'Aiuto G., Botti G., Chiodini P., Gallo C., Perrone F., de Matteis A. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009;27:3192-7.
18. Poulin R., Baker D., Labrie F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 1988;12: 213-25.
19. Ortmann J., Prifti S., Bohlmann MK., Rehberger-Schneider S., Strowitzki T., Rabe T. Testosterone and 5α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gyne-col Endocrinol 2002;16:113-20.
20. Greeve MA., Allan RK., Harvey JM., Bentel JM. Inhibition of MCF-7 breast cancer cell proliferation by 5a-dihydrotestos-terone; a role for p21(Cip1/Waf1). J Mol Endocrinol 2004;32: 793-810.
21. de Launoit Y., Dauvois S., Dufour M., Simard J., Labrie F. Inhibition of cell cycle kinetics and proliferation by the androgen 5a-dihydrotestosterone and antiestrogen N.,n-butyl-N-methyl-11-[16'α-chloro-3',17 Β-dihydroxy-estra-1'3 '5 '-(10')triene-7'α-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 1991;11:2797-802.
22. Szelei J., Jimenez J., Soto AM., Luizzi MF., Sonnenschein C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology 1997;138:1406-12.
23. Suzuki T., Darnel AD., Akahira JI., Ariga N., Ogawa S., Kaneko C., Takeyama J., Moriya T., Sasano H. 5α-Reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab 2001;86:2250-7.
24. Suzuki T., Miki Y., Moriya T., Akahira J., Ishida T., Hirakawa H., Yamaguchi Y., Hayashi S., Sasano H. 5α-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 2007;120:285-91.
25. Cops EJ., Bianco-Miotto T., Moore NL., Clarke CL., Birrell SN., Butler LM., Tilley WD. Antiproliferative actions of the synthetic androgen., mibolerone., in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol 2008;110:236-43.
26. Nicolás Diáz-Chico B., Germán Rodriguez F., González A., Ramírez R., Bilbao C., Cabrera de León A., Aguirre Jaime A., Chirino R., Navarro D., Díaz-Chico JC. Androgens and andro-gen receptors in breast cancer. J Steroid Biochem Mol Biol 2007;105:1-15.
27. Macedo LF., Guo Z., Tilghman SL., Sabnis GJ., Qiu Y., Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006;66: 7775-82.
28. Sonne-Hansen K., Lykkesfeldt AE. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J Steroid Biochem Mol Biol 2005;93:25-34.
29. Kampa M., Nifli AP., Charalampopoulos I., Alexaki VI., Theo-doropoulos PA., Stathopoulos EN., Gravanis A., Castanas E. Opposing effects of estradiol-and testosterone-membrane binding sites on T47D breast cancer cell apoptosis. Exp Cell Res 2005;307:41-51.
30. Macedo LF., Sabnis G., Brodie A. Aromatase inhibitors and breast cancer. Ann NY Acad Sci 2009;1155:162-73.
31. Dimitrakakis C., Zhou J., Wang J., Belanger A., LaBrie F., Cheng C., Powell D., Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10:292-8.
32. Hofling M., Hirschberg AL., Skoog L., Tani E., Hagerstrom T., von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007;14:183-90.
33. Peters AA., Buchanan G., Ricciardelli C., Bianco-Miotto T., Cen-tenera MM., Harris JM., Jindal S., Segara D., Jia L., Moore NL., Henshall SM., Birrell SN., Coetzee GA., Sutherland RL., Butler LM., Tilley WD. Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Res 2009;69:6131-40.
34. Birrell SN., Butler LM., Harris JM., Buchanan G., Tilley WD. Disruption of androgen receptor signaling by synthetic pro-gestins may increase risk of developing breast cancer. FASEB J 2007;21:2285-93.
35. Labrie F. Dehydroepiandrosterone., androgens and the mammary gland. Gynecol Endocrinol 2006;22:118-30.
36. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., Secreto G., Amiano P., Bingham S., Boeing H., Bueno de Mes-quita HB., Chang-Claude J., Clavel-Chapelon F., Fournier A., van Gils CH., Gonzalez CA., Gurrea AB., Critselis E., Khaw KT., Krogh V., Lahmann PH., Nagel G., Olsen A., Onland-Moret NC., Overvad K., Palli D., Panico S., Peeters P., Quirós JR., Roddam A., Thiebaut A., Tjønneland A., Chirlaque MD., Trichopoulou A., Trichopoulos D., Tumino R., Vineis P., Norat T., Ferrari P., Slimani N., Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European prospective investigation into cancer and nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
37. Micheli A., Muti P., Secreto G., Krogh V., Meneghini E., Ven-turelli E., Sieri S., Pala V., Berrino F. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004;112:312-8.
38. Eliassen AH., Missmer SA., Tworoger SS., Spiegelman D., Bar-bieri RL., Dowsett M., Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406-15.
39. Ho CC., Rohaizak M., Zulkifli SZ., Siti-Aishah MA., Nor-Aini U., Sharifah-Noor-Akmal SH. Serum sex hormone levels in pre-and postmenopausal breast cancer patients. Singapore Med J 2009;50:513-8.
40. Davis SR., Davison SL., Donath S., Bell RJ. Circulating andro-gen levels and self-reported sexual function in women. J Am Med Assoc 2005;294:91-6.
41. Davison SL., Bell R., Donath S., Montalto JG., Davis SR. Andro-gen levels in adult females: changes with age., menopause., and oophorectomy. J Clin Endocrinol Metab 2005;90:847-53.
42. Sturgeon SR., Potischman N., Malone KE., Dorgan JF., Daling J., Schairer C., Brinton LA. Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study. Cancer Causes Control 2004;15:45-53.
43. Thomas HV., Key TJ., Allen DS., Moore JW., Dowsett M., Fen-timan IS., Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopau-sal women on the island of Guernsey. Br J Cancer 1997; 75:1075-9.
44. Cauley JA., Lucas FL., Kuller LH., Stone K., Browner W., Cum-mings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of osteoporotic fractures research group. Ann Intern Med 1999;130:270-7.
45. Dorgan JF., Longcope C., Stephenson HE Jr., Falk RT., Miller R., Franz C., Kahle L., Campbell WS., Tangrea JA., Schatzkin A. Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ Health Perspect 1997; 105:583-5.
46. Manjer J., Johansson R., Berglund G., et al. Postmenopausal breast cancer risk in relation to sex steroid hormones., prolactin and SHBG (Sweden). Cancer Causes Control 2003;14: 599-607.
47. Missmer SA., Eliassen AH., Barbieri RL., Hankinson SE. Endogenous estrogen., androgen., and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-65.
48. Wang B., Mi M., Wang J., Wei N., Zhang Q., Zhu J., Yang S., Guo B., Xu J., Yang X. Does the increase of endogenous steroid hormone levels also affect breast cancer risk in Chinese women? A case-control study in Chongqing., China. Int J Cancer 2009;124:1892-9.
49. Yu H., Shu XO., Shi R., Dai Q., Jin F., Gao YT., Li BD., Zheng W. Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer 2003;105:92-7.
50. Tworoger SS., Missmer SA., Barbieri RL., Willett WC., Colditz GA., Hankinson SE. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using post-menopausal hormones. J Natl Cancer Inst 2005;97:595-602.
51. Key T., Appleby P., Barnes I., Reeves G., Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94: 606-16.
52. Hankinson SE., Eliassen AH. Endogenous estrogen., testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol 2007;106:24-30.
53. Zeleniuch-Jacquotte A., Bruning PF., Bonfrer JM., et al. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 1997;145:1030-8.
54. Zeleniuch-Jacquotte A., Shore RE., Koenig KL., Akhmedkhanov A., Afanasyeva Y., Kato I., Kim MY., Rinaldi S., Kaaks R., Tonio-lo P. Postmenopausal levels of oestrogen., androgen., and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004;90:153-9.
55. Lipworth L., Adami HO., Trichopoulos D., Carlstrom K., Mant-zoros C. Serum steroid hormone levels., sex hormone-binding globulin., and body mass index in the etiology of postmeno-pausal breast cancer. Epidemiology 1996;7:96-100.
56. Adly L., Hill D., Sherman ME., Sturgeon SR., Fears T., Mies C., Ziegler RG., Hoover RN., Schairer C. Serum concentrations of estrogens., sex hormone-binding globulin., and androgens and risk of breast cancer in postmenopausal women. Int J Cancer 2006;119:2402-7.
57. Mady EA., Ramadan EE., Ossman AA. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers 2000;16:151-7.
58. Hofling M., Lofgren L., von Schoultz E., Carlstrom K., Soder-qvist G. Associations between serum testosterone levels., cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women. Gynecol Endocrinol 2008;24:405-10.
59. Schairer C., Hill D., Sturgeon SR., Fears T., Mies C., Ziegler RG., Hoover RN., Sherman ME. Serum concentrations of estrogens., sex hormone binding globulin., and androgens and risk of breast hyperplasia in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1660-5.
60. Danforth KN., Eliassen AH., Tworoger SS., Missmer SA., Barbieri RL., Rosner BA., Colditz GA., Hankinson SE. The association of plasma androgen levels with breast., ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer 2010;126:199-207.
61. Hofling M., Ma L., Sahlin L., Haglund C., Nordling S., von Schoultz B., Cline JM. Expression of the androgen receptor and syndecan-1 in breast tissue during different hormonal treatments in cynomolgus monkeys. Climacteric 2009;12:72-9.
62. Davis SR., Hirschberg AL., Wagner LK., Lodhi I., von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J Clin Endocrinol Metab 2009;12:4907-13.
63. Jick SSDS., Hagberg KW., Kaye JADPH., Jick H. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. Obstet Gynecol 2009;113:74-80.
64. Tamimi RM., Hankinson SE., Chen WY., Rosner B., Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166: 1483-9.
65. Ness RB., Albano JD., McTiernan A., Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009;169:41-6.
66. Somboonporn W. Testosterone therapy for postmenopausal women: efficacy and safety. Semin Reprod Med 2006;24:115-24.
67. Bitzer J., Kenemans P., Mueck AO., FSDeducation Group. Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy. Matu-ritas 2008;59:209-18.
68. Dimitrakakis C., Zhou J., Bondy CA. Androgens and mammary growth and neoplasia. Fertil Steril 2002;77:26-33.
69. Dimitrakakis C., Jones RA., Liu A., Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004;11:531-5.
70. Berrino F., Pasanisi P., Bellati C., Venturelli E., Krogh V., Mas-troianni A., Berselli E., Muti P., Secreto G. Serum testosterone levels and breast cancer recurrence. Int J Cancer 2005; 113:499-502.
71. Micheli A., Meneghini E., Secreto G., Berrino F., Venturelli E., Cavalleri A., Camerini T., Di Mauro MG., Cavadini E., De Palo G., Veronesi U., Formelli F. Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol 2007;25:2685-90.
72. Rock CL., Flatt SW., Laughlin GA., Gold EB., Thomson CA., Natarajan L., Jones LA., Caan BJ., Stefanick ML., Hajek RA., Al-Delaimy WK., Stanczyk FZ., Pierce JP., Women's Healthy Eating and Living Study Group. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:614-20.
73. Tamimi RM., Byrne C., Colditz GA., Hankinson SE. Endogenous hormone levels., mammographic density., and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007;99:1178-87.
74. Walker K., Fletcher O., Johnson N., Coupland B., McCormack VA., Folkerd E., Gibson L., HiHier SG., Holly JM., Moss S., Dowsett M., Peto J., dos Santos Silva I. Premenopausal mammogra-phic density in relation to cyclic variations in endogenous sex hormone levels., prolactin., and insulin-like growth factors. Cancer Res 2009;69:6490-9.
75. Conner P., Svane G., Azavedo E., Soderqvist G., Carlström K., Gräser T., Walter F., von Schoultz B. Mammographic breast density., hormones., and growth factors during continuous combined hormone therapy. Fertil Steril 2004;6:1617-23.
76. Verheus M., Peeters PH., van Noord PA., van der Schouw YT., Grobbee DE., van Gils CH. No relationship between circulating levels of sex steroids and mammographic breast density: the prospect-EPIC cohort. Breast Cancer Res 2007;9:R53.
77. Warren R., Skinner J., Sala E., Denton E., Dowsett M., Folkerd E., Healey CS., Dunning A., Doody D., Ponder B., Luben RN., Day NE., Easton D. Associations among mammographic density., circulating sex hormones., and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15:1502-8.
78. Bremnes Y., Ursin G., Bjurstam N., Rinaldi S., Kaaks R., Gram IT. Endogenous sex hormones., prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 2007;121:2506-11.
79. McCormack VA., Dowsett M., Folkerd E., Johnson N., Palles C., Coupland B., Holly JM., Vinnicombe SJ., Perry NM., dos Santos Silva I. Sex steroids., growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res 2009;11:R38.
80. Yong M., Atkinson C., Newton KM., Aiello Bowles EJ., Stanc-zyk FZ., Westerlind KC., Holt VL., Schwartz SM., Leisenring WM., Lampe JW. Associations between endogenous sex hormone levels and mammographic and bone densities in pre-menopausal women. Cancer Causes Control 2009;20:1039-53.
81. Greendale GA., Palla SL., Ursin G., Laughlin GA., Crandall C., Pike MC., Reboussin BA. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the postmenopausal estrogen/progestin interventions mammographic density study. Am J Epidemiol 2005;162:826-34.
82. Davis SR., Wolfe R., Farrugia H., Ferdinand A., Bell RJ. The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med 2009;6:1850-6.
83. van Staa TP., Sprafka JM. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009;62:76-80.
84. Davis SR., Moreau M., Kroll R., Bouchard C., Panay N., Gass M. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005-17.
85. Jacobeit JW., Gooren LJ., Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgen-der individuals. Eur J Endocrinol 2009;161:795-8.
86. Brueggemeier RW., Hackett JC., Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005; 26:331-45.
87. Secreto G., Toniolo P., Berrino F. Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res 1991;51:2572-6.
88. Gammon MD., Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991;134:818-24.
89. Coulam CB., Annegers JF., Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61: 403-7.
90. Chang RJ. Polycystic ovary syndrome and hyperandrogenic states. In: Strauss JF., Barbieri RL., editors. Yen and Jaffe's reproductive endocrinology. 6th Edition. Philadelphia., PA: Elsevier., 2009:489-516.
91. Gammon MD., Thompson WD. Infertility and breast cancer: a population-based case-controlled study. Am J Epidemiol 1990; 132:708-16.
92. Anderson KE., Sellers TA., Chen PL., Rich SS., Hong CP., Fol-som AR. Association of Stein-Levinthal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 1997;79:494-9.
93. Pierpoint T., McKeigue PM., Isaacs AJ., Wild SH., Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581-6.
94. Gadducci A., Gargini A., Palla E., Fanucchi A., Genazzani R. Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 2005;20:200-8.
95. Chittenden BG., Fullerton G., Maheshwari A., Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod BioMed Online 2009;19: 398-404.
96. Moini A., Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. J Assist Reprod Genet 2009;26:123-7.
97. Atiomo WU., El-Mahdi E., Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril 2003; 80:143-5.
98. Hunter A., Vimplis S., Sharma A., Eid N., Atiomo W. To determine whether first-degree male relatives of women with poly-cystic ovary syndrome are at higher risk of developing cardiovascular disease and type II diabetes mellitus. J Obstet Gynaecol 2007;27:591-6.
99. Dimitrakakis C., Bondy C. Androgens and the breast. Breast Cancer Res 2009;11:212.
100. Raynaud JP., Pujos-Gautraud M., Pasqualini JR. Testosterone., other androgens and breast cancer. In: Pasqualini JP., editor. Breast cancer: prognosis., treatment., and prevention. 2nd Edition. New York: Informa Healthcare 2008:181-200.
101. Woolcott C., Shvetsov Y., Stanczyk F., Wilkens L., White K., Caberto C., Henderson B., Le Marchand L., Kolonel L., Goodman M. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic cohort study. Endocr Relat Cancer 2010;17:125-34.